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Transplantation, Merten et al. [1], writing on behalf of the
Pharmacist Workforce Working Group of the National
Marrow Donor Program’s System Capacity Initiative, discuss
the evolving role of the pharmacist in a modern hemato-
poietic stem cell transplantation (HSCT) practice and discuss
how collaborative practice agreements (CPAs) between
physicians and pharmacists may improve the efﬁciency and
quality of care in HCST. Although many of us take for granted
the interactions between pharmacists and physicians when
providing care for HSCT recipients and other patients with
complex medical and oncologic problems, even a cursory
review of modern medical history should remind us that this
critical relationship has changed signiﬁcantly and, as Merten
et al. point out, continues to evolve in modern transplant
centers.
The eminent physician-scientist Lewis Thomas thought-
fully remarked that in the early 20th century, the role of the
physician was to divine or augur, not to cure [2]. The physi-
cian’s primary role was to forecast the clinical course of
maladies, especially those that were life-threatening, given
the paucity of effective nonsurgical therapies, with thera-
peutic remedies limited primarily to analgesics and a handful
of drugs, such as digitalis, that were capable of truly altering
the course of illness. Thomas wrote of the prescriptions
written by his father in this era that “they were placebos, and
they had been the principal mainstay of medicine, the sole
technology, for so long a timedmillenniadthat they had the
incantatory power of religious ritual” [2].
In 1910, the Journal of the American Medical Association
published the second edition of the Handbook of Therapy,
a compendium of pharmacologic therapies available at the
time for various diseases [3]. As a medical student, I chanced
upon a well-preserved copy in a used bookstore in Minne-
apolis, which now sits on my ofﬁce shelf as a reminder of
how far medicine has evolved in the past century. The entire
section of the book devoted to “malignant growths” consists
of 2 pages, with most of that space devoted to the potentialFinancial disclosure: See Acknowledgments on page 506.
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certain tumors. Fortunately, other areas of medicine received
greater attention, with much more written about other
important problems, including foul breath (3 pages) and
snake poisoning (6 pages) [3].
Just over 50 years later, modern oncology and drug
therapy emerged from the shadows. Thomas and colleagues
labored to make HSCT a reality despite considerable skepti-
cism [4], and Freireich and colleagues advanced the ﬁrst
combination chemotherapies for acute lymphoid leukemia
[5]. By the end of the 1960s, NASA had landed a man on the
moon, and equivalent advances in oncology yielded reliable
cures of pediatric leukemia and the ﬁrst lasting successes
after HSCT. Since then, each subsequent decade has brought
dramatic advances in HSCT, including the further develop-
ment of effective conditioning regimens in the 1970s,
modern approaches to graft-versus-host disease prophylaxis
in the 1980s, modern autologous HSCT approaches for
myeloma and lymphoma in the 1990s, and the widespread
adoption of reduced-intensity conditioning and the growth
of cord blood transplantation in the 2000s.
In parallel with advances in conditioning and immuno-
suppression, we have seen critical developments in
supportive care, including antimicrobial chemotherapy for
bacterial, viral, and fungal diseases. At a time when the
National Marrow Donor Program is celebrating our 1
millionth transplantation performed, pharmacologic
management of HSCT recipients is more complex than ever.
As the success rate improves, HSCT is being performed in
increasingly older patients with greater comorbidities and,
consequently, more baseline medical therapies. Modern
HSCT uses a multitude of conditioning regimens and post-
transplantation therapies, incorporates increasingly complex
immunosuppressive strategies for primary graft-versus-host
disease prevention and therapy, and uses a host of drugs that
commonly interact in potentially harmful ways (eg, calci-
neurin inhibitors, antifungal azoles). It is not at all unusual
for a patient to require more than 10 medications given at
varying intervals through the day. In many cases, the indi-
vidual best trained to advise the multidisciplinary medical
team about the best drug or dose for a complex problem is
the pharmacist, not the physician.
In their enlightening review of the role of CPAs in HSCT
care, Merten et al. note that 43 states have established
speciﬁc regulatory authority for pharmacistephysician
collaboration, although the scope of this authority varies
considerably. Furthermore, the Centers for Medicare and
Medicaid Services recently recognized pharmacists as
members of the medical staff in the hospital setting, opening
the way to reimbursement for care provided by pharmacists
K.V. Komanduri / Biol Blood Marrow Transplant 19 (2013) 505e508506to manage drug therapy within a CPA. These critical prece-
dents can facilitate better integration of pharmacists into
multidisciplinary care environments, where they can provide
unique expertise while potentially reducing necessary effort
by physicians, improving both the quality and efﬁciency of
care. Their review highlights the diversity of CPAs and
provides illustrative examples, including those used at the
Veteran’s Affairs Medical Centers and at the state level in
New Mexico and North Carolina. In these examples, CPAs
allow pharmacists to provide unique services, including
direct prescriptive authority and the ability to order labora-
tory tests necessary to manage drug therapy [1]. While
highlighting evidenced-based examples of the beneﬁts of
CPAs in other disease settings, the authors also point out that
to date, few HSCT programs have implemented CPAs. A
natural consequence of this is a paucity of formalized eval-
uations of CPAs in the HSCT setting despite the many known
theoretical advantages, including improved patient educa-
tion and compliance, reduced medical errors and adverse
interactions, and improved efﬁciency of care by placing
pharmacists on the front lines of care, reducing the burden
on physicians and mid-level practitioners [1].
This enlightening review highlights helpful examples of
successful CPA implementation in the oncology setting,
including a CPA that governs ambulatory chemotherapy
administration at the University of North Carolina, Chapel
Hill. It further provides a thoughtful road map for imple-
menting a CPA, including conducting a needs assessment,
evaluating stafﬁng needs and constraints, establishing
expectations for training and supervision, and ultimately
developing and implementing the CPA. Thoughtful consid-
eration of the key elements of these steps is provided, and
although the beneﬁts are appropriately stressed, potential
pitfalls (eg, the still-nebulous situation regarding the
potential for reimbursement of services for a pharmacist
under a CPA) are discussed as well. The authors also point out
areas in which the HSCT community needs to come together
to further advance the expectations for and implementation
of CPAs.
In an era when performance-based reimbursement is
increasingly the norm, we need to better deﬁne in objective
terms the value of CPAs and the stafﬁng levels of experiencedpharmacists. This is a difﬁcult task given the heterogeneity of
practices and the lack of evidenced-based HSCT literature.
Better analyses of the ﬁnancial impact of CPAs and phar-
macist stafﬁng levels in HSCTwill be critical, considering that
administrators are increasingly required to provide ﬁnancial
justiﬁcation for most hires, even when the beneﬁts seem
obvious, such as shortened duration of visits and improved
patient satisfaction. It will also be helpful if our peer-
reviewed clinical standards (including those established by
the Foundation for the Accreditation for Cellular Therapy,
respected by academic HSCT centers and third-party payers
alike) thoughtfully consider and ultimately reﬂect the
beneﬁts of integrated efforts by pharmacists and the
appropriate role of CPAs in particular.
As a physician who has practiced in institutions in which
pharmacists were conﬁned to a satellite as well as in insti-
tutions where pharmacists directly engaged and educated
patients and ordered laboratory tests and medications in the
medical record, I am a ﬁrm believer in the increasing inte-
gration of experienced pharmacists in HSCT care. As
thoughtfully argued by Merten et al., physicianepharmacist
CPAs, if thoughtfully considered and enacted, should facili-
tate the ongoing expansion of clinical services and volume by
HSCT centers while maintaining and even increasing the
quality of care and patient satisfaction.ACKNOWLEDGMENTS
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